On Sep 20, we issued an updated research report on Illumina, Inc. (NASDAQ:ILMN) , a Zacks Rank #3 (Hold) stock. The company’s market opportunities continue to expand owing to accelerated demand from clinical and translational customers. Its recent strategic collaborations are also expected to widen its product portfolio.
Shares of the company have outperformed its industry over the past year. The stock has declined 13.6%, narrower than the industry's decrease of 24.6%.
Illumina consistently showcases robust performance across a broad range of sequencing applications. The launch of Veriseq NIPT v2 and the company’s partnership with AnchorDx in the second quarter of 2019 also buoy optimism. Meanwhile, the HiSeq to NovaSeq upgrade cycle is progressing well and the NextSeq placements are strong as well. Moreover, we are looking forward to the company's newly-inked Pacific Biosciences deal.
In the last reported quarter, the company saw a solid uptick in oncology testing on the application of genomic information. It is upbeat about 12 new drugs being introduced with a predictive biomarker (nine of which were approved for oncology indications). In 2019, we expect Illumina to progress within this space as a powerful provider of genomic testing.
In the quarter, EMEA demonstrated impressive growth of 7% with a record number of sequencing systems and sequencing consumables delivered. Despite revenues from Greater China falling 9% year over year during the period, there are currently 3-4 million NIPT tests done annually in the country.
On the flip side, HiSeq consumables persistently drop as expected. Seasonality in direct-to-consumer (DTC) functionality also continues to erode Illumina’s microarray sales. Contraction in both margins and a year-over-year deterioration in Service and Other revenues are concerns. Additionally, the company is operating in a tough competitive landscape.
Stocks Worth a Look
A few better-ranked stocks in the broader medical space are Haemonetics (NYSE:HAE) , Baxter (NYSE:BAX) and Amedisys (NASDAQ:AMED) , each carrying a Zacks Rank #2 (Buy).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Haemonetics’ long-term earnings growth rate is expected to be 7.13%.
Baxter’s long-term earnings growth rate is projected at 12.8%.
Amedisys’ long-term earnings growth rate is expected to be 16.26%.
Wall Street’s Next Amazon (NASDAQ:AMZN)
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Baxter International Inc. (BAX): Free Stock Analysis Report
Haemonetics Corporation (HAE): Free Stock Analysis Report
Illumina, Inc. (ILMN): Free Stock Analysis Report
Amedisys, Inc. (AMED): Free Stock Analysis Report
Original post